Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment

Gepotidacin is a novel triazaacenaphthylene bacterial topoisomerase inhibitor. This phase 1 nonrandomized, open‐label, multicenter, 2‐part study evaluated the pharmacokinetics, safety, and tolerability of oral gepotidacin 1500 mg in 3 different hepatic settings (normal, moderate impairment, and seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Mohammad, Tiffany, Courtney, Tao, Yu, Barth, Aline, Marbury, Thomas C., Preston, Richard A., Dumont, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248074/
https://www.ncbi.nlm.nih.gov/pubmed/33450142
http://dx.doi.org/10.1002/cpdd.913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248074/
https://www.ncbi.nlm.nih.gov/pubmed/33450142
http://dx.doi.org/10.1002/cpdd.913

Ejemplares similares